Donor DNA-free, DSB-free Precise CRISPR Gene Editing

Disease modifying somatic cell correction with minimized risk of on/off target derived indels or random integration of donor DNA.

Core Benefit

  • Target selection is free from PAM sequence constraints.
  • Ex-vivo therapy: realized by transfection of RNA or protein.
  • In-vivo therapy: Components are small enough for AAV.

Background

Although gene disruption therapy by CRISPR is actively being developed, major challenges of CRISPR to use as a tool for gene correction are to : i) ensure homology-directed repair (HDR), precise genetic change without insertion or deletion (indels) at the target site and ii) avoid off-target mutations, without scarifying gene correction efficiency.

Recently, base editing technologies were invented, in which deaminase linked with Cas9 nickase alters C to T, or A to G, but its application is limited and off-target error still exist.

Technology

Previously, we invented Single Nicking of the target Gene and Donor(SNGD) plasmid -induced surprisingly precise and efficient gene correction method (doi:10.1101/gr.226027.117). In this technology, we have taken one step further, utilized the other allele as a donner. Given that mutation points are different in two alleles of most recessive genetic disorder patients, this strategy is applicable for many of them.

Facts and Data

  • Thymidine kinase (TK) Point mutation of TK6 derived TK deficiency lymphoblast cells were corrected up to 5% by electroporation of RNA. Very few indels or off target editing were observed.
  • fibroblast cells from hereditary genome instability syndrome were gene corrected and showed normal protein expression.

Patents and Publications

  • WO/2020/100361
  • Journal in preparation

Researcher

Prof. Shinichiro Nakada, Department of Bioregulation and Cellular Response, Graduate School of Medicine, Osaka Univ., Japan

Expectations

We are seeking licensees who utilize this technology for gene therapy. Collaborative researches targeting specific diseases are welcome. Details can be disclosed under CDA.

Product No. KJ-02315

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name

Message

Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.

<Notice>

Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.